Genelux says Olvi-Vec could improve immune recognition in “cold” tumors that typically evade detection and resist immunotherapy. In company-reported data, one small cell lung cancer patient saw 84.6% tumor reduction and 16.7 months progression-free survival.
published
Genelux says Olvi-Vec could improve immune recognition in “cold” tumors that typically evade detection and resist immunotherapy. In company-reported data, one small cell lung cancer patient saw 84.6% tumor reduction and 16.7 months progression-free survival.
Latest documented BWB result
See Billy's timestamped results and follow-through.
Review the latest gains posts, original timestamps, and proof images published by Banking With Billy.
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.